Ask AI
ProCE Banner Series

Advances in Oral Targeted Therapies for HR+/HER2- Breast Cancer: Best Practices for Oncology Pharmacists

This 1-hour webinar will provide expert perspectives on oral targeted therapies for HR-positive/HER2-negative breast cancer, including the latest safety and efficacy evidence, best practices for adverse event monitoring and management, and strategies to support treatment adherence and persistence to improve patient outcomes.

  ACPE-P
Who Should Attend

This activity has been designed to meet the educational needs of oncology pharmacists and other healthcare professionals caring for patients with breast cancer.

All Events

Advances in Oral Targeted Therapies for HR+/HER2- Breast Cancer: Best Practices for Oncology Pharmacists

Upcoming Events

May

19

2026

12:00 PM - 1:00 PM Eastern Time (ET)

Virtual

Additional Info

There are no fees required to participate in this activity.

Americans With Disabilities Act 
Event staff will be glad to assist you with any special needs (eg, physical, dietary). Please contact customer support prior to the live event.

CME/CE Info

Goal Statement
This activity aims to improve learners’ knowledge, confidence, and competence in monitoring and managing adverse events related to oral targeted therapies to maximize treatment adherence/persistence and therapeutic benefit in patients HR-positive/HER2-negative breast cancer. 

Target Audience
This activity has been designed to meet the educational needs of oncology pharmacists and other healthcare professionals caring for patients with breast cancer. 

Learning Objectives
Upon completion of this event, participants should be able to:

  • Apply the latest safety and efficacy evidence for oral targeted therapies to clinical practice to individualize the management of patients with HR-positive/HER2-negative breast cancer
  • Collaborate with patients, caregivers, and the multidisciplinary team to use evidence-based approaches for monitoring and managing adverse events associated with oral targeted therapies for HR-positive/HER2-negative breast cancer
  • Support adherence/persistence to oral targeted therapies in patients with HR-positive/HER2-negative breast cancer through expert-recommended communication strategies, tools, and resources

Accreditation

CE Accreditation

ProCE, LLC is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. ACPE Universal Activity Number 0221-0000-26-005-L01-P has been assigned to this live application-based activity (initial release date May 19, 2026). This activity is approved for 1.0 contact hour (0.1 CEU) in states that recognize ACPE providers. This activity is provided at no cost to participants. Participants must complete the activity evaluation within 30 days of the activity to receive pharmacy CE credit. No partial credit will be given. Statements of completion will be issued online at www.deceraclinical.com/education, and proof of completion will be posted in NABP CPE Monitor profiles.

Disclosure of Conflicts of Interest
ProCE, LLC requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to ProCE policy. ProCE is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

Acknowledgement

Provided by

Provided by ProCE, LLC.

ProCE, LLC

Supporters

Supported by an educational grant from AstraZeneca.

AstraZeneca

For customer support please click here.

Mailing Address:

 

Decera Clinical
12001 Sunrise Valley Drive
Suite 304
Reston, VA 20191